Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Rel. Chemotex
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 92.14 | 79.68 | 90.02 | 89.40 | 85.50 | 102.27 | 92.57 | 91.60 | 92.23 | 82.20 | 92.36 | 99.52 | 81.94 |
| Expenses + | 85.24 | 70.85 | 81.03 | 82.46 | 78.09 | 94.57 | 86.72 | 85.51 | 83.26 | 70.84 | 81.60 | 89.24 | 71.24 |
| Operating Profit | 6.90 | 8.83 | 8.99 | 6.94 | 7.41 | 7.70 | 5.85 | 6.09 | 8.97 | 11.36 | 10.76 | 10.28 | 10.70 |
| OPM % | 7.49% | 11.08% | 9.99% | 7.76% | 8.67% | 7.53% | 6.32% | 6.65% | 9.73% | 13.82% | 11.65% | 10.33% | 13.06% |
| Other Income + | 3.12 | 1.46 | 1.08 | 0.81 | 0.95 | 1.43 | 4.13 | 3.75 | 0.56 | 1.72 | 0.39 | 0.36 | 0.40 |
| Interest | 2.90 | 4.89 | 4.75 | 4.81 | 4.92 | 5.08 | 6.34 | 6.03 | 5.91 | 5.83 | 6.50 | 5.88 | 6.32 |
| Depreciation | 2.44 | 2.63 | 2.52 | 2.52 | 2.53 | 2.56 | 3.46 | 3.48 | 3.50 | 4.22 | 3.69 | 3.70 | 3.70 |
| Profit before tax | 4.68 | 2.77 | 2.80 | 0.42 | 0.91 | 1.49 | 0.18 | 0.33 | 0.12 | 3.03 | 0.96 | 1.06 | 1.08 |
| Tax % | 33.12% | 0.00% | 21.07% | -9.52% | 92.31% | 69.13% | -233.33% | -327.27% | -58.33% | 38.94% | -11.46% | -55.66% | 25.93% |
| Net Profit + | 3.13 | 2.77 | 2.23 | 0.46 | 0.06 | 0.46 | 0.59 | 1.42 | 0.19 | 1.84 | 1.06 | 1.65 | 0.80 |
| EPS in Rs | 4.15 | 3.67 | 2.96 | 0.61 | 0.08 | 0.61 | 0.78 | 1.88 | 0.25 | 2.44 | 1.41 | 2.19 | 1.06 |
Financials of Rel. Chemotex
Annual income statement trend
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 250 | 235 | 257 | 291 | 285 | 323 | 300 | 256 | 362 | 364 | 366 | 357 | 356 |
| Expenses + | 227 | 224 | 238 | 269 | 265 | 298 | 271 | 232 | 317 | 329 | 335 | 325 | 313 |
| Operating Profit | 23 | 11 | 19 | 22 | 19 | 26 | 28 | 23 | 45 | 35 | 31 | 32 | 43 |
| OPM % | 9% | 5% | 7% | 8% | 7% | 8% | 9% | 9% | 12% | 10% | 8% | 9% | 12% |
| Other Income + | 3 | 17 | 3 | 4 | 1 | 2 | 1 | 4 | 3 | 6 | 4 | 10 | 3 |
| Interest | 11 | 13 | 13 | 14 | 12 | 13 | 11 | 10 | 12 | 14 | 20 | 24 | 25 |
| Depreciation | 6 | 6 | 7 | 7 | 7 | 7 | 7 | 8 | 9 | 10 | 10 | 15 | 15 |
| Profit before tax | 9 | 9 | 2 | 5 | 1 | 8 | 11 | 10 | 27 | 17 | 6 | 4 | 6 |
| Tax % | 40% | 28% | -48% | -35% | -217% | 49% | 13% | 33% | 34% | 26% | 43% | -11% | |
| Net Profit + | 6 | 7 | 3 | 6 | 3 | 4 | 9 | 7 | 18 | 12 | 3 | 4 | 5 |
| EPS in Rs | 7.08 | 8.14 | 3.16 | 8.10 | 3.25 | 5.11 | 12.37 | 9.19 | 24.03 | 16.46 | 4.26 | 5.37 | 7.10 |
| Dividend Payout % | 7% | 6% | 16% | 6% | 15% | 15% | 8% | 22% | 10% | 15% | 24% | 9% |
Financials of Rel. Chemotex
Capital structure and asset base
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 29 | 32 | 32 | 64 | 66 | 63 | 91 | 97 | 114 | 124 | 126 | 130 | 132 |
| Borrowings + | 85 | 107 | 113 | 95 | 94 | 82 | 65 | 97 | 128 | 199 | 281 | 263 | 252 |
| Other Liabilities + | 37 | 48 | 53 | 64 | 63 | 69 | 65 | 61 | 84 | 66 | 66 | 74 | 87 |
| Total Liabilities | 154 | 191 | 201 | 227 | 228 | 218 | 227 | 263 | 333 | 397 | 481 | 474 | 479 |
| Fixed Assets + | 82 | 107 | 109 | 152 | 145 | 140 | 136 | 148 | 181 | 196 | 318 | 313 | 306 |
| CWIP | 2 | 2 | 1 | 0 | 0 | 0 | 6 | 1 | 10 | 39 | 1 | 0 | 1 |
| Investments | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 66 | 79 | 91 | 76 | 82 | 79 | 85 | 113 | 142 | 162 | 163 | 162 | 172 |
| Total Assets | 154 | 191 | 201 | 227 | 228 | 218 | 227 | 263 | 333 | 397 | 481 | 474 | 479 |
Financials of Rel. Chemotex
Operating, investing and financing cash movement
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 17 | 0 | 12 | 32 | 11 | 26 | 22 | 27 | 59 | -0 | 18 | 11 |
| Cash from Investing Activity + | -5 | -27 | -6 | -2 | -0 | -0 | -8 | -43 | -74 | -51 | -82 | 33 |
| Cash from Financing Activity + | -14 | 28 | -6 | -30 | -11 | -26 | -13 | 15 | 14 | 55 | 60 | -43 |
| Net Cash Flow | -2 | 1 | 0 | -0 | -1 | -0 | 1 | -0 | -0 | 4 | -4 | 0 |
| Free Cash Flow | 10 | -29 | 5 | 28 | 10 | 25 | 15 | 12 | 9 | -54 | -75 | 2 |
| CFO/OP | 86% | 18% | 68% | 152% | 62% | 105% | 83% | 118% | 140% | 7% | 62% | 32% |
Financials of Rel. Chemotex
Working capital efficiency and return ratios
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 26 | 21 | 30 | 23 | 22 | 20 | 16 | 15 | 5 | 7 | 6 | 18 |
| Inventory Days | 58 | 93 | 102 | 85 | 97 | 74 | 82 | 138 | 91 | 87 | 104 | 145 |
| Days Payable | 47 | 70 | 84 | 79 | 84 | 70 | 65 | 58 | 57 | 28 | 32 | 58 |
| Cash Conversion Cycle | 37 | 44 | 48 | 30 | 36 | 24 | 33 | 95 | 40 | 67 | 78 | 105 |
| Working Capital Days | 14 | 21 | 0 | -19 | -22 | -11 | -12 | -42 | -62 | -81 | -58 | -27 |
| ROCE % | 17% | 16% | 10% | 12% | 8% | 13% | 14% | 11% | 19% | 11% | 7% | 7% |
6,216.3 lakhs, a 40.2% YoY increase from Rs. Key investor presentation takeaways from Iris Clothings Ltd's Q2 FY27 investor presentation — and how it ranks agai
6.0% growth). Key results statement takeaways from Damodar Industries's Q2 FY27 results statement — and how it ranks against sector peers.
H1 FY27 Net Sales: ₹1,303.46 Mn, up 56.0% YoY from ₹836.84 Mn in H1 FY26 (Page 23). Key investor presentation takeaways from Forcas Studio Ltd's Q2 FY27 investo
Q2 FY 26 Total Income (Revenue) reported at INR 207.4 Cr, up 35% year-on-year versus Q2 FY 25 revenue of INR 153.7 Cr (Page 10). Key investor presentation takea